RxDoctor Payments Data

Alicia Alvarez, MD

Allergy & Immunology · Sarasota, FLNPI 1538519707

Payments from drug & device makers

$2,951in general payments, 2019–2025

Across 114 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$762
  • Regeneron Healthcare Solutions, Inc.$335
  • CSL Behring$318
  • AstraZeneca$219
  • GSK$208
  • Takeda Pharmaceuticals U.S.A., Inc.$184
  • plus $924 from 16 others

What the payments were for

  • Consulting fees$211%
  • Food & beverage$2,89798%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,951 in reported general payments places this provider in the 40th percentile of 204 allergy & immunology providers in Florida.

See all allergy & immunology providers in Florida

Medicare billing

Part B allowed, 2024
$81,665
Medicare patients
364
Services billed
4,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$46,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$42,677
Breo ElliptaFluticasone/Vilanterol32$17,613
Epinephrine38$8,413
Wixela InhubFluticasone Propion/Salmeterol37$4,713
Azelastine Hcl100$4,264
Ipratropium Bromide77$3,329
BreynaBudesonide/Formoterol Fumarate12$3,209
SymbicortBudesonide/Formoterol Fumarate11$2,770
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,240
Fluticasone Propionate104$2,133
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,678
Mometasone Furoate20$1,483
Albuterol Sulfate HfaAlbuterol Sulfate39$1,114
Montelukast Sodium56$805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$208$60,29075 claims
AstraZenecaSymbicort$219$2,77011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 204 allergy & immunology providers in Florida.

Other allergy & immunology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →